Early tissue transglutaminase-mediated response underlies K562(S)-cell gliadin-dependent agglutination

Pediatric Research

Volumn 71, Issue 5, 2012, Pages 532-538

  Silano, Marco ^a   Vincentini, Olimpia ^a   Luciani, Alessandro ^b   Felli, Cristina ^a   Caserta, Sergio ^c   Esposito, Speranza ^b   Villella, Valeria Rachela ^c   Pettoello Mantovani, Massimo ^b   Guido, Stefano ^c   Maiuri, Luigi ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CALCIUM ION; GLIADIN; GLIADIN DERIVED PEPTIDE[31-43]; LIPOCORTIN 5; PEPTIDE DERIVATIVE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CELIAC DISEASE; CELL AGGLUTINATION; CELL STRAIN; CELL STRAIN K562(S); CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; INTESTINE EPITHELIUM; PRIORITY JOURNAL; TOXICITY TESTING;

CELL ADHESION; ENZYME ACTIVATION; GLIADIN; HUMANS; K562 CELLS; TRANSGLUTAMINASES;

EID: 84859915672     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2012.4     Document Type: Article

References (35)

1. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137:1912-33.
2. Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest 2007;117:41-9. (Pubitemid 46048448)
3. Green PH, Cellier C. Celiac disease. N Engl J Med 2007;357:1731-43.
4. Londei M, Ciacci C, Ricciardelli I, Vacca L, Quaratino S, Maiuri L. Gliadin as a stimulator of innate responses in celiac disease. Mol Immunol 2005;42:913-8. (Pubitemid 40489015)
5. Meresse B, Ripoche J, Heyman M, Cerf-Bensussan N. Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis. Mucosal Immunol 2009;2:8-23.
6. Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003;362:30-7. (Pubitemid 36835817)
7. Giovannini C, Sanchez M, Straface E, Scazzocchio B, Silano M, De Vincenzi M. Induction of apoptosis in caco-2 cells by wheat gliadin peptides. Toxicology 2000;145:63-71. (Pubitemid 30190267)
8. De Ritis G, Occorsio P, Auricchio S, Gramenzi F, Morisi G, Silano V. Toxicity of wheat flour proteins and protein-derived peptides for in vitro developing intestine from rat fetus. Pediatr Res 1979;13:1255-61. (Pubitemid 9256292)
9. Silano M, De Vincenzi M. In vitro screening of food peptides toxic for coeliac and other gluten-sensitive patients: a review. Toxicology 1999;132:99-110. (Pubitemid 29121948)
10. De Vincenzi M, Stammati A, Luchetti R, Silano M, Gasbarrini G, Silano V. Structural specificities and significance for coeliac disease of wheat gliadin peptides able to agglutinate or to prevent agglutination of K562(S) cells. Toxicology 1998;127:97-106. (Pubitemid 28341820)
11. Silano M, DesséM, De Vincenzi M, Cornell H. In vitro tests indicate that certain varieties of oats may be harmful to patients with coeliac disease. J Gastroenterol Hepatol 2007;22:528-31. (Pubitemid 46434973)
12. Clemente MG, De Virgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003;52:218-23. (Pubitemid 36115062)
13. Maiuri L, Ciacci C, Ricciardelli I, et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005;129:1400-13. (Pubitemid 41597382)
14. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534-9. (Pubitemid 35279599)
15. Collighan RJ, Griffin M. Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 2009;36:659-70.
16. Luciani A, Villella VR, Vasaturo A, et al. Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminasemediated PPARgamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 2010;59:311-9.
17. Villanacci V, Not T, Sblattero D, et al. Mucosal tissue transglutaminase expression in celiac disease. J Cell Mol Med 2009;13:334-40.
18. Silano M, De Vincenzi M. Bioactive antinutritional peptides derived from cereal prolamins: a review. Nahrung 1999;43:175-84. (Pubitemid 129570445)
19. Dieterich W, Trapp D, Esslinger B, et al. Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut 2003;52:1562-6. (Pubitemid 37363438)
20. Gawaz M, Ott I, Reininger AJ, Heinzmann U, Neumann FJ. Agglutination of isolated platelet membranes. Arterioscler Thromb Vasc Biol 1996;16:621-7. (Pubitemid 26153105)
21. Kiráy R, Csosz E, Kurtá T, et al. Functional significance of five noncanonical Ca2+-binding sites of human transglutaminase 2 characterized by site-directed mutagenesis. FEBS J 2009;276:7083-96.
22. O'Neill GM, Prasanna Murthy SN, Lorand L, et al. Activation of transglutaminase in mu-calpain null erythrocytes. Biochem Biophys Res Commun 2003;307:327-31. (Pubitemid 36818873)
23. Painter RG, Ginsberg M. Concanavalin A induces interactions between surface glycoproteins and the platelet cytoskeleton. J Cell Biol 1982;92: 565-73. (Pubitemid 12157429)
24. Vlodavsky I, Sachs L. Difference in the calcium regulation of concanavalin A agglutinability and surface microvilli in normal and transformed cells. Relationship to membrane-cytoskeleton interaction. Exp Cell Res 1977;105:179-89. (Pubitemid 8066461)
25. Yagi M, Campos-Neto A, Gollahon K. Morphological and biochemical changes in a hematopoietic cell line induced by jacalin, a lectin derived from Artocarpus integrifolia. Biochem Biophys Res Commun 1995;209: 263-70.
26. Quaroni A, Beaulieu JF. Cell dynamics and differentiation of conditionally immortalized human intestinal epithelial cells. Gastroenterology 1997;113:1198-213. (Pubitemid 27418974)
27. Drago S, El Asmar R, Di Pierro M, et al. Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006;41:408-19. (Pubitemid 43675406)
28. Reinke Y, Behrendt M, Schmidt S, Zimmer KP, Naim HY. Impairment of protein trafficking by direct interaction of gliadin peptides with actin. Exp Cell Res 2011;317:2124-35.
29. Reinke Y, Zimmer KP, Naim HY. Toxic peptides in Frazer's fraction interact with the actin cytoskeleton and affect the targeting and function of intestinal proteins. Exp Cell Res 2009;315:3442-52.
30. Barone MV, Zanzi D, Maglio M, et al. Gliadin-mediated proliferation and innate immune activation in celiac disease are due to alterations in vesicular trafficking. PLoS ONE 2011;6:e17039.
31. Barone MV, Nanayakkara M, Paolella G, et al. Gliadin peptide P31-43 localises to endocytic vesicles and interferes with their maturation. PLoS ONE 2010;5:e12246.
32. Barone MV, Gimigliano A, Castoria G, et al. Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease. Gut 2007;56:480-8. (Pubitemid 46580502)
33. Ohba H, Toyokawa T, Yasuda S, Hoshino T, Itoh K, Yamasaki N. Spectroscopic analysis of the cytoagglutinating activity of abrin-b isolated from Abrus precatorius seeds against leukemic cells. Biosci Biotechnol Biochem 1997;61:737-9. (Pubitemid 27312718)
34. Luciani A, Villella VR, Vasaturo A, et al. SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 2009;183:2775-84.
35. Fico A, Manganelli G, Simeone M, Guido S, Minchiotti G, Filosa S. Highthroughput screening-compatible single-step protocol to differentiate embryonic stem cells in neurons. Stem Cells Dev 2008;17:573-84. (Pubitemid 351948192)